Inhibikase Therapeutics Raises $100M Through Public Offering
ByAinvest
Friday, Nov 21, 2025 3:14 am ET1min read
IKT--
Inhibikase Therapeutics has priced an underwritten public offering of 46.1 million shares and pre-funded warrants to purchase 22.9 million shares at $1.45 per share. The offering is expected to raise approximately $100 million in gross proceeds. The pre-funded warrants are priced at $0.9999 per share and will be exercisable immediately. The offering is expected to close on or around February 22, 2023.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet